CN1814116A - Chinese medicine for treating gastric cavity ache and preparing method - Google Patents
Chinese medicine for treating gastric cavity ache and preparing method Download PDFInfo
- Publication number
- CN1814116A CN1814116A CN 200510007343 CN200510007343A CN1814116A CN 1814116 A CN1814116 A CN 1814116A CN 200510007343 CN200510007343 CN 200510007343 CN 200510007343 A CN200510007343 A CN 200510007343A CN 1814116 A CN1814116 A CN 1814116A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- weight portions
- weight portion
- weight
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for curing gastral cavity ache, composed of medicinal composition and/or pharmaceutically acceptable carrier, where the medicinal composition is prepared of the follow raw materials: Radix Bupleuri, Yanhusuo, Bitter Orange, Nutgrass Galingale Rhizome, White Paeony Root andLiquorice Root, and it has efficacies of comforting liver and regulating Qi and moderating stomach and stopping pain, able to be applied to curing liver depression and Qi stasis, gastral cavity ache, etc. And the invention also discloses a method for preparing the medicine.
Description
Technical field
The present invention relates to a kind of Chinese medicine for the treatment of gastric abscess, the invention still further relates to this preparation method of Chinese medicine.
Background technology
Gastric abscess mainly is the chronic disease of outbreak repeatedly, incoordination between the spleen and stomach is main pathomechanism, the fire that is edema with the liver involved is negligent of letting out, the stagnation of QI does not reach, and perverse and unreasonable manner is violated stomach, stomach-QI being unable to descend normally, stomach receiving food and drink, digesting food, a surname is logical unsuitable, as surfeit fertilizer, sweet, fortunately, peppery or polyphagia is raw and cold or hungry full impermanence all can cause the gastric qi retardance.Prior art has the nano energy-stagnation stomachache electuary, the patent No. 01100075.9, the invention discloses a kind of nano energy-stagnation stomachache treating medicine, it is to be raw material with nano bupleurum, nanometer Fructus Aurantii, the nanometer Radix Paeoniae Alba, nanometer Radix Glycyrrhizae, nano cyperus tuber, nanometer Rhizoma Corydalis, and new pharmaceutical preparation is made in preparation in proportion, its fineness of the particles reaches the 1200-1500 order, particle diameter is 0.1-200nm, and wherein most particle diameters are less than 100nm, and has new rerum natura.Adopt steps such as microwave extracting, concentrating under reduced pressure, supersonic jet technology spray drying to make.This drug bioavailability height, therapeutic effect is remarkable.We are through a large amount of clinical trial, have found a kind of combination of components of specific consumption of Chinese medicine for the treatment of gastric abscess, have best curative effect, thereby have finished the present invention.
Summary of the invention
One of purpose of the present invention provides a kind of medicine of treatment gastric abscess of better efficacy.
Another purpose of the present invention provides the preparation method of this medicine.
Chinese medicine of the present invention is made up of active ingredient and/or pharmaceutically acceptable carrier, and wherein said active ingredient is made by following raw materials according: Radix Bupleuri 30-140 weight portion, Rhizoma Corydalis 50-160 weight portion, Fructus Aurantii 40-140 weight portion, Rhizoma Cyperi 30-160 weight portion, Radix Paeoniae Alba 30-180 weight portion and Radix Glycyrrhizae 10-90 weight portion.
The active component that preferred following raw materials according is made, curative effect is better:
Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions.
Preferably with Rhizoma Corydalis, Rhizoma Cyperi and Radix Glycyrrhizae respectively big gun process.
Each method of the active ingredient system of Chinese medicine of the present invention can be that raw material is dry respectively, and levigation mixes.It also can be the conventional method preparation of adopting herbal pharmaceutical.These pharmacy conventional methods can be water extract-alcohol precipitation or ethanol extract from water precipitation, also have other extracting method in addition, specifically " pharmaceutics of Chinese drugs " published referring to Cao Chunlin chief editor's Shanghai science tech publishing house.
The following preparation method preparation of preferred employing: except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, each 0.5-4 hour, collecting decoction, filter, filtrate is concentrated into clear paste, adds above-mentioned fine powder mixing, drying under reduced pressure, pulverize, add right amount of auxiliary materials, mixing, granulate, promptly.
Effective ingredient of the present invention can be prepared into oral formulations such as granule, capsule, tablet, oral liquid, effervescent tablet, dispersible tablet etc. with acceptable accessories.
Effective ingredient of the present invention has liver-smoothing, qi-regulating, stomach function regulating analgesic effect.Can be used for treating stagnation of QI due to depression of the liver, feeling of stuffiness in chest distension, gastralgia.
The specific embodiment
Embodiment 1: the preparation of tablet
Take by weighing Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions; Except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, each 0.5-4 hour, collecting decoction filters, and filtrate is concentrated into clear paste, add above-mentioned fine powder mixing, drying under reduced pressure is pulverized, and adds right amount of auxiliary materials, mixing, granulate, compacting is in blocks, promptly.
Embodiment 2: the preparation of capsule
Take by weighing Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions; Except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, each 0.5-4 hour, collecting decoction filters, and filtrate is concentrated into clear paste, add above-mentioned fine powder mixing, drying under reduced pressure is pulverized, and adds right amount of auxiliary materials, mixing, granulate, encapsulated, promptly.
Embodiment 3: the preparation of granule
Take by weighing Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions; Except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, and each 0.5-4 hour, collecting decoction filtered, filtrate is concentrated into clear paste, adds above-mentioned fine powder mixing, and drying under reduced pressure is pulverized, add right amount of auxiliary materials, mixing is granulated, promptly.
Embodiment 4: the preparation of dispersible tablet
Take by weighing Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions; Except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, and each 0.5-4 hour, collecting decoction filtered, filtrate is concentrated into clear paste, adds above-mentioned fine powder mixing, and drying under reduced pressure is pulverized, and adds right amount of auxiliary materials, mixing is granulated, tabletting, promptly.
Experimental example 1:
This patent invention is pressed described clinical trial protocol in the time in 2 years according to this, select treatment case 231 examples altogether, and according to originally pressing the clinical trial protocol of being formulated, carry out clinical observation and summary, receive significant curative effect, and carried out physico-chemical examinations such as the heart, liver, kidney for the treatment patient and do not found any toxic and side effects, now the clinical trial situation is summarized as follows.
Its concrete clinical trial protocol is:
One, case selection
(1) diagnostic criteria
1, tcm diagnosis standard (with reference to general education Chinese medicine class planning teaching material sixth version " Chinese Internal Medicine ")
(1) conscious gastral cavilty portion painful abdominal mass plug, distension or distending pain discomfort.
(2) onset is slow, the time heavy when light, show effect repeatedly more than 2 months.
(3) morbidity is often become rusty because of relevant with diet, feelings will, daily life, cold temperature etc.
All possess above (1) (2), promptly diagnosable with reference to (3) and other symptoms, tongue fur, pulse condition.
2, traditional Chinese medical science sign diagnostic criteria
(1) traditional Chinese medical science sign diagnostic criteria
Incoordination between the liver and stomach disease:
Primary symptom: the gastral cavilty distension, uncomfortable in chest, sighing frequently often increases the weight of because of feelings will factor.
Inferior disease: attack to scurry and have a pain, lead to both sides of the chest, the belch of feeling sick, it is not well to defecate, white and thin fur, arteries and veins is profound.
Feeling of fullness symptom scalar quantization table:
| Symptom | Gently | In | Heavy |
| Gastral cavilty or Wan distention and fullness in the abdomen Ai gas sour regurgitation n and V sighing frequently stool uncomfortable in chest is not smooth | Slight turgor; The time Zhi during Zuo, do not affect work and the even You Ai gas acid regurgitation of the having a rest slight even You uncomfortable in chest that feels sick once in a while heaves a deep sigh and defecates that slightly You is not smooth | Distension obviously but can stand, the time outbreak arranged, have nauseating when the belch acid regurgitation is arranged when influencing work and rest, idol has vomiting uncomfortable in chest obviously, the time see that the direct stimulation of the heaving a deep sigh outbreak stool of then heaving a deep sigh is not smooth | Distension unbearably, continue more than, it is nauseating again and again often need to take the frequent belch acid regurgitation of the food stagnation removing agents alleviate of regulating the flow of vital energy, and vomits uncomfortable in chest obviously not smooth as stopping up the frequency work stool of heaving a deep sigh sometimes |
3, Western medicine diagnose standard:
(1) chronic gastritis diagnostic criteria [with reference to " internal disease diagnostic criteria " (.1992.8 of Shanghai science tech publishing house)]
A, clinical manifestation chronic gastritis lack specific symptom, mostly are the indigestion symptom of outbreak repeatedly greatly;
B, gastroscopy superficial gastritis determine that diagnosis is a foundation with the mirror pathology alive of mucosa under gastroscopic observation and the scope.
The hyperemia of superficial gastritis mucosa diffusivity, edema, exudative mucosa liquid adhere to, last subcutaneous hemorrhage point, rotten to the corn (flatness or protuberance property)
Slightly: mucosa mild hyperaemia edema, visible sometimes a small amount of subcutaneous hemorrhage point of going up.
Moderate: the mucous hyperemia edema is apparent in view, and visible more last subcutaneous hemorrhage point (greater than 10 points)/or rotten to the corn.
Severe: the mucous hyperemia edema is remarkable, and visible more flatness erosion (greater than 10 points), and often presents lamellar, and the erosion of protuberance property is also more.
C, pathologic finding and calibration standard thereof
Hp density: distinguish degree according to Hp distribution and density.
Do not have: on the specific stain sheet, rake about and do not see Hp.
Slightly: gastric mucosa surface epithelium and the accidental Hp of little recessed epithelial surface, or see minority Hp less than the superficial epithelium and the little recessed epithelial surface of 1/3 length.
Moderate: superficial epithelium and little recessed epithelial surface greater than 1/3 length are seen Hp, or Hp is like seriality, the thin and sparse surface that is present in.
Severe: Hp is present in superficial epithelium in heaps and little recessed epithelial surface is seen.
A) chronic inflammatory disease
Slightly: mononuclear cell (lymphocyte, plasma cell and macrophage) is confined to the mucosa shallow-layer.
Moderate: the mononuclear cell limitation surpasses 1/3 of mucous layer, reaches 2/3.
Severe: mononuclear cell occupies the mucosa holostrome, and comparatively dense.
B) activeness inflammation
Slightly: proper mucous membrane has the minority neutrophil infiltration.
Moderate: the more mucous layer that is present in of neutrophilic granulocyte, and see between superficial epithelium iuntercellular, little recessed epithelium table iuntercellular or the adjacent several glandular tube epitheliums of mucous layer.
Severe: neutrophilic granulocyte is intensive, or except that the moderate finding, also sees more " little recessed abscess.
(2) include standard in
(1) meets the Western medicine diagnose standard.
(2) meet the tcm diagnosis standard
(3) treat the disease characteristics according to the object of the invention and the present invention, the age is in the case of 20-50 between year.
(4) agree to participate in clinical research of the present invention notice in the know.
In this hospital, select to meet the patient of chronic gastritis according to national new Chinese medicine clinical guidance principle, meet Western medicine diagnose standard and traditional Chinese medical science disease diagnostic criteria person, select 20-50 year patient, and be signed with the patient of Informed Consent Form, 231 examples.
Wherein male case 121 people, women case 110 people are divided into two groups at random, first group of 116 people, wherein male case 47 people, women case 69 people, 48.7 years old mean age, medical history 23.6 months; Second group of totally 115 people, wherein male case 54 people, women case 61 people, 44.5 years old mean age, medical history 12.6 months.First group is the clinical control group, and patient takes gastropine, 3 times/day/people, and each two.Second group is treatment group of the present invention, and patient takes medicine of the present invention, 3 times/day/people, and each four.Treat, be two months the course of treatment.
(3) exclusion standard
(1) dialectical indeterminate or too much merger disease arranged
(2) merge serious primary disease such as the heart, brain, liver, kidney and hemopoietic system, psychotic.
(3) allergic constitution and to multiple drug allergy person.
(4) can not be by the medicine that exhausts the course of treatment
Two, observation index
(1) safety observation
(1) general health check-up project detects
(2) blood, urine, just routine examination
(3) heart, liver, kidney function test
(4) untoward reaction that may occur and relevant detection index thereof
(2) health giving quality observation
1, related symptoms and sign
2, relevant physico-chemical examination
(1) gastroscope and pathologic finding
(2) X ray examination
(3) gastrointestinal motility functional check
Three, efficacy determination
(1) curative effect of disease criterion
1, clinical recovery clinical symptoms, sign disappear, and it is normal that physico-chemical examination recovers.
2, the clinical cardinal symptom of produce effects, sign disappear substantially, and integration reduces more than 2/3, and physico-chemical examination obviously improves.
3, effectively cardinal symptom, sign alleviate, and integration reduces more than 1/3, and physico-chemical examination makes moderate progress.
4, invalidly do not reach above-mentioned effective standard or deterioration person.
(2) card marquis curative effect judging standard
1, clinical recovery clinical symptoms, sign disappear, and the disease integration reduces 〉=95%
2, produce effects clinical symptoms, sign are obviously improved, and the disease integration reduces 〉=70%;
3, effectively clinical symptoms, sign are obviously improved, and the disease integration reduces 〉=30%
4, invalid clinical symptoms, sign all do not have obvious improvement, even increase the weight of, and card Hou Jifen reduces less than 30%;
Annotate: computing formula (nimodipine method) is { integration * 100%} before (preceding integration-treatment back integration)/treatment
(2) therapeutic evaluation of cardinal symptom and clinical physico-chemical examination index
(1) clinic control end course of treatment back clinical symptom disappearance
(2) produce effects end course of treatment back symptom classification reduces 2 grades
(3) effectively finish back symptom classification the course of treatment and reduce 1 grade
(4) invalidly do not reach above-mentioned standard person
Four, therapeutic outcome
(1) sick clinical trial result;
Table 1: curative effect of disease result of the test
| Test item | Group | Obvious effective rate | Effective percentage | Inefficiency | The statistical disposition significance relatively between group |
| Disease Clinical detection index and card marquis curative effect | The treatment group | 85.42 | 92.31 | 7.69 | P＜0.01 |
| Matched group | 78.32 | 86.74 | 13.26 |
(2) card marquis curative effect judging standard
1, the card marquis judges scoring score value standard:
Disease complete obiteration 0 minute
Sign is according to light 2 minutes in the classification amount ornamental column
Sign was according in the classification amount ornamental column 4 minutes
Sign is according to heavy 5 minutes in the classification amount ornamental column
2, card marquis curative effect statistical table;
| Clinical indices | Group | Mean scores | Difference statistical disposition significance relatively before and after the treatment | ||
| Before the treatment | After the treatment | Difference | |||
| Gastral cavilty or distension and fullness in the abdomen | The treatment group | 3.56 | 1.24 | 2.32 | P＜0.05 |
| Matched group | 2.92 | 2.35 | 0.57 | ||
| It is not smooth to defecate | The treatment group | 4.31 | 2.15 | 2.16 | P＜0.05 |
| Matched group | 4.14 | 3.26 | 0.88 | ||
| The belch acid regurgitation | The treatment group | 3.43 | 1.65 | 1.78 | P＜0.05 |
| Matched group | 3.38 | 2.23 | 1.15 | ||
| Nausea and vomiting | The treatment group | 3.91 | 1.35 | 2.56 | P＜0.05 |
| Matched group | 3.15 | 1.79 | 1.36 | ||
| Sighing frequently | The treatment group | 4.57 | 1.33 | 3.24 | P＜0.05 |
| Matched group | 3.99 | 3.12 | 0.87 | ||
| Uncomfortable in chest | The treatment group | 4.50 | 2.19 | 2.31 | P＜0.05 |
| The treatment group | 4.31 | 3.28 | 1.03 | P＜0.05 |
(3) cardinal symptom and efficacy result:
1, the curative effect classification of cardinal symptom and clinical physico-chemical examination index
Do nothing 0 grade
Slightly be 1 grade
Moderate is 2 grades
Severe is 3 grades
| Clinical indices | Group | Level mark statistics (classification fraction meansigma methods) | Difference statistical disposition significance relatively before and after the treatment | ||
| Before the treatment | After the treatment | Difference | |||
| The classification of gastroscopy superficial gastritis | The treatment group | 2.87 | 1.25 | 1.62 | P＜0.05 |
| Matched group | 2.69 | 2.02 | 0.67 | ||
| The classification of pathologic finding chronic inflammatory disease | The treatment group | 2.73 | 0.92 | 1.81 | P＜0.05 |
| Matched group | 2.94 | 1.86 | 1.08 | ||
| The classification of pathologic finding activeness | The treatment group | 2.59 | 1.06 | 1.53 | P＜0.05 |
| Matched group | 2.39 | 1.81 | 0.58 | ||
Sum up: from the result of clinical trial, the total effective rate of Drug therapy stagnation of QI gastric abscess of the present invention is 92.31%, obvious effective rate is 85.42%, all be higher than matched group, learn by statistics and handle, significant difference (P＜0.05) is arranged, and it is remarkable to illustrate that the present invention treats stagnation of QI gastric abscess disease effects.
Claims (6)
1. Chinese medicine for the treatment of gastric abscess, it is characterized in that being made up of active ingredient and/or pharmaceutically acceptable carrier, wherein said active ingredient is made by following raw materials according: Radix Bupleuri 30-140 weight portion, Rhizoma Corydalis 50-160 weight portion, Fructus Aurantii 40-140 weight portion, Rhizoma Cyperi 30-160 weight portion, Radix Paeoniae Alba 30-180 weight portion and Radix Glycyrrhizae 10-90 weight portion.
2. Chinese medicine according to claim 1, it is characterized in that with Rhizoma Corydalis, Rhizoma Cyperi and Radix Glycyrrhizae respectively big gun process.
3. according to the described medicine of claim 1-2, the raw material that wherein prepares described active ingredient comprises: Radix Bupleuri 90 weight portions, Rhizoma Corydalis 100 weight portions, Fructus Aurantii 100 weight portions, Rhizoma Cyperi 100 weight portions, the Radix Paeoniae Alba 120 weight portions and Radix Glycyrrhizae 50 weight portions.
4. according to the described Chinese medicine of claim 1-3, it is characterized in that adopting following method to make: except that Rhizoma Corydalis 3-30 weight portion, Radix Paeoniae Alba 6-40 parts by weight of crushed become the fine powder, Six-elements such as all the other Fructus Aurantiis decoct with water 1-7 time, each 0.5-4 hour, collecting decoction filtered, filtrate is concentrated into clear paste, add above-mentioned fine powder mixing, drying under reduced pressure is pulverized, add right amount of auxiliary materials, mixing is granulated, promptly.
5. according to any one described Chinese medicine among the claim 1-4, it is characterized in that being oral formulations.
6. Chinese medicine according to claim 5 is characterized in that granule, capsule, tablet, oral liquid, effervescent tablet or dispersible tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510007343 CN1814116A (en) | 2005-02-06 | 2005-02-06 | Chinese medicine for treating gastric cavity ache and preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510007343 CN1814116A (en) | 2005-02-06 | 2005-02-06 | Chinese medicine for treating gastric cavity ache and preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1814116A true CN1814116A (en) | 2006-08-09 |
Family
ID=36906548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510007343 Pending CN1814116A (en) | 2005-02-06 | 2005-02-06 | Chinese medicine for treating gastric cavity ache and preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1814116A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408067C (en) * | 2005-02-23 | 2008-08-06 | 辽宁本溪三药有限公司 | Chinese medicines for stomach pain due to Qi stagnation and its preparing method |
| CN103494919A (en) * | 2013-10-16 | 2014-01-08 | 刘运波 | Traditional Chinese medicine for treating stomachache |
| CN105999211A (en) * | 2016-05-05 | 2016-10-12 | 南京素德问医药科技有限公司 | Cream for soothing liver-gallbladder |
-
2005
- 2005-02-06 CN CN 200510007343 patent/CN1814116A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100408067C (en) * | 2005-02-23 | 2008-08-06 | 辽宁本溪三药有限公司 | Chinese medicines for stomach pain due to Qi stagnation and its preparing method |
| CN103494919A (en) * | 2013-10-16 | 2014-01-08 | 刘运波 | Traditional Chinese medicine for treating stomachache |
| CN103494919B (en) * | 2013-10-16 | 2015-06-03 | 刘运波 | Traditional Chinese medicine for treating stomachache |
| CN105999211A (en) * | 2016-05-05 | 2016-10-12 | 南京素德问医药科技有限公司 | Cream for soothing liver-gallbladder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1250255C (en) | Chinese herbal medicine combination for treating disease of disorder of bowels's function and its product | |
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1683001A (en) | Chinese medicine for treating gout | |
| CN1775274A (en) | Cough-relieving sputum-resolving medicinal composition and preparing method | |
| CN1814116A (en) | Chinese medicine for treating gastric cavity ache and preparing method | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN1304735A (en) | Medicine for curing chronic colitis | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN1276767C (en) | Traditional Chinese medicine for treating non-alcoholic simple fatty liver and its preparation method | |
| CN1254267C (en) | Medicine for treating gastral cavity pain and its preparation method | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1157219C (en) | Medicine for treating cancer | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1628770A (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN100335042C (en) | Preparation technology of mammary healthy dispersion tablet | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN1840008A (en) | Chinese medicinal granule for clearing pharynx and moistening throat and preparation method thereof | |
| CN1493350A (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN1283492A (en) | Tibetan medicine for treating hepatism and its preparing process | |
| CN1557415A (en) | Medicine preparation for treating liver and gallbladder disease and its preparing process | |
| CN1303981C (en) | Preparation method of Fuyankang medicine for treating gynecopathy | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN1299752C (en) | Traditional Chinese medicine capsule for treating urinary calculus and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |